Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Modified FOLFIRINOX in Metastatic Biliary Tract Cancer
NCT03778593Phase 2Completed
- Start
- Mar 2019
- Primary completion
- Mar 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and fluorouracil in biliary tract cancer (BTC). Primary endpoint: Response rate of treated participants at 6 months. Started Mar 2019; status: completed.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03778593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778593.